Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 25597487)

Published in Muscle Nerve on June 03, 2015

Authors

Jay J Han1, Gregorij Kurillo1,2, Richard T Abresch1, Evan De Bie1, Alina Nicorici1, Ruzena Bajcsy2

Author Affiliations

1: Department of Physical Medicine and Rehabilitation, School of Medicine, University of California at Davis, 4860 Y Street, Suite 3850, Sacramento, California, 95817, USA.
2: Department of Electrical Engineering and Computer Science, College of Engineering, University of California at Berkeley, Berkeley, California, USA.

Articles cited by this

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32

Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27

Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG) Am J Ind Med (1996) 16.45

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol (2009) 8.42

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet (2011) 7.53

Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med (2011) 5.91

An objective and standardized test of hand function. Arch Phys Med Rehabil (1969) 4.67

Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol (2013) 4.57

Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health (2003) 4.37

Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13

Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol (2003) 3.46

Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve (2006) 2.98

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve (2010) 2.78

Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol (2012) 2.77

Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology (2012) 2.50

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve (2013) 2.47

Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil (1995) 2.45

Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord (2008) 2.23

North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord (2010) 2.14

Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve (1981) 2.06

Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology (1989) 1.90

Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) (2011) 1.84

The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil (2011) 1.71

Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep (2009) 1.68

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve (2013) 1.63

A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord (2005) 1.44

Measuring disability of the upper extremity: a rationale supporting the use of a regional outcome measure. J Hand Ther (2000) 1.36

Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol (2013) 1.30

A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. Dev Med Child Neurol (2012) 1.20

Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer. Phys Ther (1988) 1.15

Quality of life in Duchenne muscular dystrophy: the subjective impact on children and parents. J Child Neurol (2011) 1.13

Normative and validation studies of the Nine-hole Peg Test with children. Percept Mot Skills (2000) 1.12

6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes. PLoS One (2014) 1.11

Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs (2012) 1.11

Functional stability of the glenohumeral joint. Man Ther (2000) 1.10

Muscular dystrophy: new challenges and review of the current clinical trials. Curr Opin Pediatr (2013) 1.09

Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord (2012) 1.09

The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol (1993) 1.09

Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases. PLoS One (2012) 1.07

Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care (2013) 1.05

Neuro-QOL and the NIH Toolbox: implications for epilepsy. Therapy (2010) 1.04

Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve (2007) 1.02

Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int (2001) 1.00

Quality-of-life measures in children with neurological conditions: pediatric Neuro-QOL. Neurorehabil Neural Repair (2011) 0.98

Anatomy and biomechanics of the shoulder. Orthop Clin North Am (2000) 0.97

Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by Kinect. Muscle Nerve (2014) 0.94

A kinematic model of the shoulder complex to evaluate the arm-reachable workspace. J Biomech (2006) 0.93

Genotype/phenotype correlations in Duchenne/Becker dystrophy. Mol Cell Biol Hum Dis Ser (1993) 0.92

The Duchenne dystrophy story: from phenotype to gene and potential treatment. J Child Neurol (1989) 0.90

Validity, Reliability, and Sensitivity of a 3D Vision Sensor-based Upper Extremity Reachable Workspace Evaluation in Neuromuscular Diseases. PLoS Curr (2013) 0.90

Duchenne muscular dystrophy--Meryon's disease. Neuromuscul Disord (1993) 0.87

Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study. JAMA (1992) 0.87

Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy. PLoS Curr (2013) 0.87

Gene therapy prospects for Duchenne muscular dystrophy. Eur Neurol (1994) 0.83

Tele-MFAsT: Kinect-Based Tele-Medicine Tool for Remote Motion and Function Assessment. Stud Health Technol Inform (2014) 0.81